Back to search results
Recruiting

Psoriasis

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

AMAJ | {{ defaultRegistry.registryAnchorText }} NCT03535194 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.

Time Commitment

The study will last about 56 weeks with 12 week follow-up and may include up to 20 visits.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years
  • Participant must have chronic plaque psoriasis for at least 6 months
  • Participant must not be breastfeeding or nursing
  • Participant must not have had serious or chronic/recurring infection within 3 months
  • Participant must not have any other skin conditions (excluding psoriasis)
  • Participant must not have previous exposure to Cosentyx, Taltz, Stelara, or similar medications

Where to Participate

Where to Participate

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
{{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
{{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
{{site.siteStatus | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.